Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四 環 醫 藥 控 股 集 團 有 限 公 司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT
SUCCESSFUL RENEWAL AND INCLUSION OF THE INNOVATIVE DRUG ANJIUWEI IN THE 2025 NRDL

The board of directors (the "**Board**") of Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**" or "**Sihuan Pharmaceutical**", together with its subsidiaries, the "**Group**") is pleased to announce that, following the simple medical insurance renewal with the National Healthcare Security Administration (the "**NHSA**"), the Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei), an innovative drug independently developed by Xuanzhu Biopharmaceutical Co., Ltd. ("**Xuanzhu Biopharm**"), a non wholly-owned subsidiary of Sihuan Pharmaceutical, will continue to be included in the new edition of the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (2025) (the "**2025 NRDL**") which is effective from January 1, 2026.

As the first and only proton pump inhibitor independently developed, Anjiuwei has been approved to be launched in the People's Republic of China ("**PRC**") in June 2023 for the treatment of duodenal ulcers and was first included in the National Reimbursement Drug List in December 2023. The successful renewal of the 2025 NRDL for Anjiuwei will be beneficial in stabilizing the market sales, and continue to benefit additional patient groups and enhance the penetration rate of the product in relevant indications, injecting momentum to the long-term growth of Anjiuwei.

ABOUT THE ANAPRAZOLE SODIUM ENTERIC-COATED TABLETS

The Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei) obtained market approval from the National Medical Products Administration in June 2023 for the treatment of patients with duodenal ulcers. Anaprazole Sodium features an innovative structural design, characterized by non-enzymatic plus multi-enzymatic metabolism, balanced double-channel excretion via the intestinal and renal pathways with only 3.5% is metabolized by CYP2C19, making it unaffected by the gene polymorphism of CYP2C19. Compared with previous generations of proton pump inhibitors, Anaprazole Sodium is a proton pump inhibitor that is more suitable for Chinese people as it reduces risk of combination therapy, being a safer treatment option for patients on multiple medications and those with renal insufficiency. As a national Class 1 innovative drug, Anaprazole Sodium has filled the gap in the domestic independently developed proton pump inhibitors, offering patients in China treatment options that combine improved efficacy and safety profile. In addition to the approved indication for duodenal ulcer, the Phase III clinical trial of Anaprazole Sodium Enteric-coated Tablets for the treatment of reflux esophagitis commenced in full swing in July 2025.

ABOUT XUANZHU BIOPHARM

Xuanzhu Biopharm is the innovative drug subsidiary of Sihuan Pharmaceutical. It is an innovative pharmaceutical company with roots in China and a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the research and development, production and commercialization of class 1 drugs with core proprietary intellectual property rights. The company has a first-class research and development ("**R&D**") team, all core personnel have years of experience in new drug research and development. The company has two R&D platforms: small molecule chemistry and large molecule biologics. The dual engines drive the company's innovation and development, forming a product pipeline that covers small molecule chemistry, large molecule biopharmaceuticals, antibody-drug conjugate (ADC) and other types of products. With a focus on unmet major clinical needs, the company is committed to developing into a first-class innovative pharmaceutical company with independent research and development, production, and sales capabilities.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, December 8, 2025

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.